PMID: 11920502Mar 29, 2002Paper

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

Cancer
Victoria J SinibaldiMario A Eisenberger

Abstract

Recent clinical trials have shown antitumor activity with the combination of docetaxel plus estramustine phosphate (EMP) in the treatment of patients with androgen independent prostate carcinoma (AIPC). However, the most commonly employed treatment schedules with EMP have been associated with significant gastrointestinal, cardiovascular, and thromboembolic toxicity. The authors hypothesized that the therapeutic index of the combination of docetaxel plus EMP for patients with prostate carcinoma could be enhanced by reducing the incidence and severity of EMP-associated toxicity, which could be accomplished by shortening the duration of exposure to EMP. To preserve the therapeutic synergism between docetaxel and EMP, they designed a regimen employing higher doses of oral EMP administered on the day of the docetaxel infusion. From June 1, 1998 through September 28, 2000, 42 patients with AIPC were registered to receive docetaxel (70 mg/m2 intravenously over 1 hour) and EMP (280 mg orally every 6 hours x 5 doses) every 21 days, up to a maximum of 6 cycles. Dexamethasone was administered prior to docetaxel and coumadin 2 mg orally every day was taken during the study treatment period. Patient characteristics included a median age of ...Continue Reading

References

Nov 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G R HudesR Comis
Aug 17, 1989·The New England Journal of Medicine·E D CrawfordP J Goodman
Mar 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A EisenbergerM A Friedman
Jan 1, 1986·The Prostate·B Hartley-Asp, E Kruse
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K J PientaL E Flaherty
May 4, 1994·Journal of the National Cancer Institute·L A SpeicherK D Tew
Sep 19, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G R HudesC McAleer
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D P PetrylakC A Olsson
Mar 17, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W KreisV Vinciguerra
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C N Coleman, J B Mitchell
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D C SmithK J Pienta
Oct 2, 2001·CA: a Cancer Journal for Clinicians·R T GreenleeM Thun

❮ Previous
Next ❯

Citations

May 19, 2005·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Joan Carles GalceránAtika Girard
Mar 22, 2007·Cancer Chemotherapy and Pharmacology·Yoshihiro WadaShoichi Ueda
Nov 3, 2009·Cancer Chemotherapy and Pharmacology·Trine Zeeberg Buch-HansenLisa Sengeloev
Apr 25, 2009·International Journal of Clinical Oncology·Norihito SogaYoshiki Sugimura
Sep 12, 2007·Investigational New Drugs·Joseph G KattanUNKNOWN Cancer Research Group
Jan 9, 2009·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Carol M MoinpourYoshio Nakamura
Apr 26, 2005·Current Oncology Reports·Andrew J Armstrong, Michael A Carducci
May 26, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A González-MartínA Moyano
May 12, 2005·Urologic Oncology·Alfredo BerrutiUNKNOWN Gruppo Onco-Urologico Piemontese, Rete Oncologica Piemontese
Aug 23, 2002·Critical Reviews in Oncology/hematology·Cora N Sternberg
Feb 14, 2006·Nature Clinical Practice. Urology·Niklas J Mackler, Kenneth J Pienta
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Aug 31, 2004·Japanese Journal of Clinical Oncology·Wen-Chyi SheenYung-Chang Lin
Jun 5, 2003·Current Opinion in Oncology·Jonathan Rosenberg, Eric J Small
Jul 22, 2004·American Journal of Therapeutics·James Gulley, William L Dahut
Apr 9, 2008·American Journal of Clinical Oncology·Haruhito AzumaYoji Katsuoka
Jul 20, 2012·Biochemistry Research International·Eleftheria TsakalozouYounsoo Bae
May 17, 2003·Clinical Therapeutics·S James Matthews, Christopher McCoy
Aug 30, 2008·Wiener klinische Wochenschrift·Michael RauchenwaldMichael Krainer
Mar 11, 2005·Expert Review of Anticancer Therapy·Teodoro SavaGian Luigi Cetto
Jun 5, 2003·Expert Opinion on Pharmacotherapy·Eli Rosenbaum, Michael A Carducci
Nov 30, 2002·Expert Opinion on Investigational Drugs·Janet R Walczak, Michael A Carducci
Dec 3, 2013·Critical Reviews in Oncology/hematology·Shouki BazarbashiAli Shamseddine
Oct 23, 2012·The Urologic Clinics of North America·Mario A Eisenberger, Emmanuel S Antonarakis
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Hielke J MeulenbeldRonald de Wit
Apr 25, 2006·The Urologic Clinics of North America·Earle F Burgess, Bruce J Roth
Nov 4, 2004·BJU International·C Hennequin
Sep 23, 2009·International Journal of Urology : Official Journal of the Japanese Urological Association·Rishi NayyarNarmada P Gupta

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.